Published in Blood Weekly, June 6th, 2002
Antirejection therapy is usually based on the addition of one or more adjunctive agents, such as steroids, mycophenolate mofetil, or rapamycin, to a cornerstone immunosuppressant such as Prograf or ciclosporin.
When rapamycin was first launched, however, there were concerns that it might not be appropriate to use it in combination with Prograf due to hypothetical similarities in the mode of action of the two agents. These concerns have since been dispelled, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.